Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
about
Antisense mediated splicing modulation for inherited metabolic diseases: challenges for deliveryRecurrent deep intronic mutations in the SLC12A3 gene responsible for Gitelman's syndromeTargeting RNA splicing for disease therapy.Alternative splicing: role of pseudoexons in human disease and potential therapeutic strategies.New insights in gene-derived therapy: the example of Duchenne muscular dystrophy.Potential therapeutic applications of antisense morpholino oligonucleotides in modulation of splicing in primary immunodeficiency diseasesNeurofibromatosis type 1: diagnosis and recent advances.Role of pseudoexons and pseudointrons in human cancer.Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.Regulation of telomerase alternative splicing: a target for chemotherapyModulation of aberrant NF1 pre-mRNA splicing by kinetin treatment.In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2.The third international meeting on genetic disorders in the RAS/MAPK pathway: towards a therapeutic approach.A mild neurofibromatosis type 1 phenotype produced by the combination of the benign nature of a leaky NF1-splice mutation and the presence of a complex mosaicism
P2860
Q26830637-093F441F-E9B4-46DD-A623-634CC7BD240BQ34858031-0CA732FE-A714-4111-A93B-0F53A6359036Q36780738-835739D9-3788-4CC7-A658-18BDDA92C481Q37677072-F99D9672-0749-45B1-8069-9372F2170718Q37814437-D1CEFCEF-1495-440B-BA72-A997841A17A1Q37819299-1D7956CB-BEF3-47BD-8FC6-C5257CF71C70Q38089870-88C84C30-59AE-4B70-B0CC-889600CD5285Q38160844-415AE81C-7A44-4E83-A053-DF6807D1D822Q38186137-049C05D5-F9E4-4479-8ACE-1D0383552AF0Q39170483-5ADD299C-3061-4830-B207-01BA97934172Q39771109-696D0028-DD49-474D-B904-F47D0F6B7FE9Q41830290-2026A5D1-4A13-449B-8C37-F52CAB3BCCFDQ53072085-1A52336C-351C-4A84-9966-7F7479A733E7Q57881740-C72CAE83-D99E-4E3E-81AC-31F0B5BA4E4F
P2860
Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
@en
Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
@nl
type
label
Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
@en
Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
@nl
prefLabel
Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
@en
Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
@nl
P2093
P2860
P356
P1433
P1476
Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
@en
P2093
Ana Benavides
Aurora Sánchez
Belén Canet
Conxi Lázaro
Eduard Serra
Feliciano J Ramos
Gabriel Capellá
Juana Fernández-Rodríguez
Llúcia Benito
P2860
P304
P356
10.1002/HUMU.20933
P577
2009-03-01T00:00:00Z